TRANSCRIPTOME-BASED BIOMARKERS IN HUMAN OSTEOARTHRITIS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。研究人员将收集骨性关节炎(OA)和类风湿性关节炎(RA)患者或正常人的血液、DNA、血清蛋白等，以供以后评估与OA或RA相关的变化。这是由美国国立卫生研究院发起的一项更大的计划的一部分，目的是收集这些样本，希望能够检测到一个合理特异的OA或RA活动标志物。血液，DNA，RNA从PBMC，血清以及滑液和组织将被收集和储存，并通过微阵列技术或蛋白质组学方法进行分析。目前，对于骨性关节炎的进展或活动尚无良好的标记物，人们普遍认识到，在缺乏容易的血清或其他标记物的情况下，有效的药物治疗几乎不可能取得进展。这是美国国立卫生研究院赞助的五项研究之一，旨在开发OA疾病活动的生物标记物。此外，由于DNA将用于可能的遗传分析，血清等将用于蛋白质组分析，因此也可能进行其他类型的分析。方法：方法简单明了。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The investigators will collect blood, DNA, serum proteins, etc from patients with osteoarthritis (OA) and rheumatoid arthritis (RA) or normals for later evaluation of changes associated with OA or RA. This is part of a larger protocol sponsored by the NIH to collect these samples in hopes that a reasonably specific marker of OA or RA activity can be detected. Blood, DNA, RNA from PBMCs, serum as well as synovial fluid and tissue will be collected and banked and analyzed by microarray technologies or proteomics approaches. At present there are no good markers for progression or activity of OA, and it is generally appreciated that little progress in effective drug therapies can be made in the absence of easy serum or other markers to follow. This is one of five NIH-sponsored studies designed to develop biomarkers for OA disease activity. In addition, because DNA will be available for possible genetic analysis and serum, etc for proteomic analysis, it will be possible to perform other sorts of analysis as well. Approach: The approach is simple and straightforward.